Study Results Support the use of TellDx to Personalize Cancer Care Management –-- Clinical study published in Cancer Discovery --ANDOVER, ...

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...

Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive ...

Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...

Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

Figure illustrating how circulating tumor cells (CTCs) evade immune defenses in the bloodstream by upregulating immune checkpoints, altering MHC class I expression, forming clusters, and interacting ...

The researchers found that within 4 months after blood collection, all 8 participants who scored positively with a multicancer early detection (MCED) test were diagnosed with cancer. HealthDay News — ...

We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...